We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · July 13, 2021

Oral Hormonal Male Contraceptive Prototype



Additional Info

Acceptability of the Oral Hormonal Male Contraceptive Prototype, 11β-Methyl-19-Nortestosterone Dodecylcarbonate (11β-MNTDC), in a 28-Day Placebo-Controlled Trial
Contraception 2021 Jun 18;[EPub Ahead of Print], BT Nguyen, F Yuen, M Farrant, A Thirumalai, F Fernando, JK Amory, RS Swerdloff, BD Anawalt, DL Blithe, JE Long, PY Liu, ST Page, C Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading